century. time magazine had chosen einstein, the great scientist. charles disagreed. he picked churchill, the statesman who led the fight against hitler and sounded the alarm over religion. that might explain why he traded a medical career to a one-way ticket to washington, and while once here his eyes locked on to a wanted ad in the new republic. i showed it to my wife and i said why don t you apply. and i said how can i apply, i ve never written anything and i don t know anybody. she said you write it and you hand deliver it. that day at my office at the imh i get a call. i m mike kinsley at the new republic, why do you want to do this? you are a doctor. kinsley was looking for a managing editor for the
i don t know that there s yet enough really concrete evidence of cannabis s benefit that s satisfactory. at least in that context. i think it s going to come. but it could be slow going. the fda has been great at approving studies. but national institute of drug abuse has been really stonewalling and blocking any studies looking at therapeutic effects of cannabis, because that s not their mandate. their mandate is to look at the harms of drug use. it s very easy to blame an organization. dr. nora volkow, who is the director of nida says they are not standing in the way. she claims they are not the only government institute that approves marijuana research. if you would come up with a grant that says, okay, this is going to be a treatment for drug addiction, then go to us, but if it s cancer, it goes to the cancer institute. if it is schizophrenia, it goes to imh, the institutes have a mission with certain diseases. what is clear, there are bureaucratic hoops that most
of cannabis s benefit that s satisfactory. at least in that context. i think it s going to come. but it could be slow going. the fda has been great at approving studies. but national institute of drug abuse has been really stonewalling and blocking any studies looking at therapeutic effects of cannabis, because that s not their mandate. their mandate is to look at the harms of drug use. it s very easy to blame an organization. dr. nora volkow, who is the director of nida says they are not standing in the way. she claims they are not the only government institute that approves marijuana research. if you would come up with a grant that says, okay, this is going to be a treatment for drug addiction, then go to us, but if it s cancer, it goes to the cancer institute. if it is schizophrenia, it goes to imh, the institutes have a mission with certain diseases. what is clear, there are bureaucratic hoops that most researchers simply don t want to jump through. neuroscientist carl
happen in the united states? i don t know that there s yet enough really concrete evidence of cannabis s benefit that s satisfactory. at least in that context. i think it s going to come. but it could be slow going. the fda has been great at approving studies. but national institute of drug abuse has been really stonewalling and blocking any studies looking at therapeutic effects of cannabis, because that s not their mandate. their mandate is to look at the harms of drug use. it s very easy to blame an organization. dr. nora volkow, who is the director of nida says they are not standing in the way. she claims they are not the only government institute that approves marijuana research. if you would come up with a grant that says, okay, this is going to be a treatment for drug addiction, then go to us, but if it s cancer, it goes to the cancer institute. if it is schizophrenia, it goes to imh, the institutes have a
the fda has been great at approving studies. but national institute of drug abuse has been really stonewalling and blocking any studies looking at therapeutic effects of cannabis, because that s not their mandate. their mandate is to look at the harms of drug use. it s very easy to blame an organization. dr. nora volkow, who is the director of nida says they are not standing in the way. she claims they are not the only government institute that approves marijuana research. if you would come up with a grant that says, okay, this is going to be a treatment for drug addiction, then go to us, but if it s cancer, it goes to the cancer institute. if it is schizophrenia, it goes to imh, the institutes have a mission with certain diseases. what is clear, there are bureaucratic hoops that most researchers simply don t want to jump through. neuroscientist carl hart. there are not many people studying marijuana. it s very difficult to get approved to study marijuana.